TCM

how big is TCM?

As of October 2023, TCM Ltd has a market capitalization of 29.58 Cr, categorizing it as a Micro Cap company, with recent net sales of 26.01 Cr and net profit of 1.62 Cr over the last four quarters. Shareholder's funds are reported at 28.79 Cr, and total assets amount to 83.79 Cr as of March 2024.

Market Cap: TCM Ltd has a market capitalization of 29.58 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 26.01 Cr. The sum of Net Profit for the same period is 1.62 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 28.79 Cr, while Total Assets amount to 83.79 Cr.

Who are in the management team of TCM?

As of March 2023, the management team of TCM includes Managing Director Joseph Varghese, Executive Director Ramesh Babu, and Company Secretary Gokul V Shenoy, along with several directors, both independent and non-independent, overseeing the company's operations and strategy.

As of March 2023, the management team of TCM includes the following members:<BR><BR>1. **Joseph Varghese** - Managing Director<BR>2. **Ramesh Babu** - Executive Director<BR>3. **Gokul V Shenoy** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several directors on the board, including:<BR><BR>- **George Varghese** - Non-Executive & Non-Independent Director<BR>- **Rani Jose** - Non-Executive & Non-Independent Director<BR>- **Gopalakrishnan Mahesh** - Independent Director<BR>- **Jose Jacob** - Independent Director<BR>- **Sreenivasa Bhat** - Independent Director<BR>- **Bobby John** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Has TCM declared dividend?

No Dividend History Available

Who are the peers of the TCM?

Peers of TCM include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Sonal Adhesives, Venlon Enterprises, Vinyoflex, and Omkar Pharmachem. GHCL shows excellent management risk, while TCM has below average growth and a 1-year return of -17.17%.

Peers: The peers of TCM are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Sonal Adhesives, Venlon Enterpris, Vinyoflex, and Omkar Pharmachem.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar and GHCL, and Average management risk is present at Tata Chemicals, India Glycols, Sonal Adhesives, and Vinyoflex, with Fischer Medical having Below Average management risk. Below Average growth is noted at Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, and Vinyoflex, while Average growth is seen at Fischer Medical and Sonal Adhesives. Capital Structure ratings show Excellent at GHCL, Good at Fischer Medical and Vinyoflex, Average at Tata Chemicals, India Glycols, and Sonal Adhesives, and Below Average at Chemplast Sanmar and TCM, with Venlon Enterpris and Omkar Pharmachem not qualifying.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.92%, while TCM has a 1-year return of -17.17%, which is lower than all peers except for Chemplast Sanmar, Sonal Adhesives, and Vinyoflex. Additionally, the six-month returns are negative for Tata Chemicals, Chemplast Sanmar, Sonal Adhesives, Vinyoflex, and TCM.

Is TCM overvalued or undervalued?

As of April 25, 2023, TCM is considered risky and overvalued with a PE Ratio of 18.69 and an EV to EBITDA of -19.11, significantly underperforming compared to peers like UPL and BASF India, and has a year-to-date return of -14.82% versus the Sensex's 5.59%.

As of 25 April 2023, TCM's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company is currently assessed as overvalued given its financial ratios and performance metrics. Key ratios include a PE Ratio of 18.69, an EV to EBITDA of -19.11, and a ROE of 5.31%. <BR><BR>In comparison to peers, TCM's valuation stands out unfavorably; for instance, UPL, which is rated as attractive, has a PE Ratio of 38.74 and an EV to EBITDA of 8.35. Similarly, BASF India, also attractive, shows a PE Ratio of 45.64 and an EV to EBITDA of 28.4. Furthermore, TCM's recent stock performance has lagged behind the Sensex, particularly in the year-to-date return of -14.82% compared to the Sensex's 5.59%, reinforcing the notion that TCM is overvalued in the current market context.

What is the technical trend for TCM?

As of June 5, 2025, TCM's technical trend has shifted to a bearish stance with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mixed momentum indicators.

As of 5 June 2025, the technical trend for TCM has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the bearish signals from the daily moving averages and the Bollinger Bands on both weekly and monthly time frames. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, indicating mixed momentum. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall bearish outlook. The Dow Theory indicates a mildly bullish stance on the weekly but no trend on the monthly, suggesting uncertainty in the longer term. Overall, the bearish trend is supported by the prevailing indicators despite some mixed signals.

What does TCM do?

TCM Ltd is a micro-cap company involved in trading and installing solar panels, healthcare products, and manufacturing cattle feed. As of March 2025, it reported net sales of 76 Cr and a net profit of 40 Cr, with a market cap of INR 30 Cr.

Overview: <BR>TCM Ltd is engaged in the trading and installation of solar panels, health care products, and the manufacturing of cattle feed, operating within the commodity chemicals industry and classified as a micro-cap company.<BR><BR>History: <BR>Incorporated in April 1943, TCM Ltd was formerly known as Travancore Chemical & Mfg. Co. Ltd. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 76 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 40 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 30 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 40 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.35 <BR>Return on Equity: 5.31% <BR>Price to Book: 0.99 <BR><BR>Contact Details: <BR>Address: 28/2917 Aiswarya Shanthi Nagar, Ponneth Temple Road Cochin Kerala : 682020 <BR>Tel: 91-0484-2316771 <BR>Email: info@tcmlimited.in <BR>Website: http://www.tcmlimited.in

Who are the top shareholders of the TCM?

The top shareholder of TCM is Joseph Varghese, holding 49.48%, with no pledged promoter holdings. The highest public shareholder is Lici Asm Non Par at 7.41%, while individual investors collectively own 38.8% of the shares.

The top shareholders of TCM include the promoters, with Joseph Varghese holding the largest share at 49.48%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors currently do not hold any shares in the company. The highest public shareholder is Lici Asm Non Par, who owns 7.41%. Additionally, individual investors collectively hold 38.8% of the shares.

When is the next results date for TCM?

The next results date for TCM is 11 November 2025.

The next results date for TCM is scheduled for 11 November 2025.

Are TCM latest results good or bad?

TCM's latest Q2 FY26 results are concerning, showing a net loss of -₹2.24 crores and a 58.04% drop in revenue quarter-on-quarter. The company's operational inefficiencies and shift in business model raise serious doubts about its future viability.

TCM's latest results for Q2 FY26 are quite concerning. The company reported a net profit of -₹2.24 crores, which is a significant decline of 155.58% compared to the previous quarter. Year-on-year, there was an increase of 128.57%, but this is overshadowed by the current losses. Revenue also saw a dramatic drop, falling 58.04% quarter-on-quarter to ₹3.21 crores, and down 39.20% year-on-year from ₹5.28 crores.<BR><BR>The operating margin has deteriorated sharply, now at -61.06%, compared to -19.70% in the same quarter last year, indicating severe operational inefficiencies. Similarly, the PAT margin is at -73.21%, a stark contrast to the previous year's figures.<BR><BR>Overall, these results reflect a catastrophic quarter for TCM, with significant operational challenges and a business model that appears to be fundamentally broken. The company's transformation from chemical manufacturing to a diversified trading model has not yielded sustainable profitability, raising serious concerns about its future viability.

How has been the historical performance of TCM?

TCM's historical performance shows significant fluctuations, with net sales peaking at 32.23 Cr in March 2024 before declining to 26.01 Cr in March 2025. However, the company reported a recovery in profitability, achieving a profit after tax of 1.40 Cr in March 2025, up from a loss of 2.29 Cr the previous year.

Answer:<BR>The historical performance of TCM shows significant fluctuations in its financial metrics over the years, with a notable recovery in recent periods.<BR><BR>Breakdown:<BR>TCM's net sales peaked at 32.23 Cr in March 2024 but fell to 26.01 Cr in March 2025, following a substantial increase from just 7.35 Cr in March 2023. The total operating income mirrored this trend, reaching 32.23 Cr in March 2024 before declining to 26.01 Cr in March 2025. The company's total expenditure, excluding depreciation, was 28.17 Cr in March 2025, down from 34.47 Cr in March 2024, indicating a reduction in costs. Despite this, TCM reported an operating profit (PBDIT) of 2.31 Cr in March 2025, a recovery from a loss of 1.81 Cr in March 2024. The profit before tax also improved to 1.37 Cr in March 2025, compared to a loss of 2.25 Cr in the previous year. Consequently, the profit after tax turned positive at 1.40 Cr in March 2025, reversing a loss of 2.29 Cr in March 2024. The consolidated net profit for March 2025 was 1.61 Cr, a significant improvement from the loss of 1.95 Cr in March 2024. TCM's total assets decreased to 76.40 Cr in March 2025 from 83.79 Cr in March 2024, while total liabilities also fell to 76.40 Cr from 83.79 Cr, indicating a stabilization in the company's financial position. The cash flow from operating activities was negative at -10.00 Cr in March 2025, although cash flow from financing activities showed a positive inflow of 10.00 Cr. Overall, TCM's financial performance reflects a recovery trajectory, with improvements in profitability metrics despite challenges in sales and cash flow.

Should I buy, sell or hold TCM Ltd?

Why is TCM Ltd falling/rising?

As of 18-Jan, TCM Ltd's stock price is slightly rising at 58.10, reflecting a short-term positive trend despite a significant 13.08% decline over the past month and ongoing financial challenges. The stock's recent performance may be temporary, overshadowed by its weak long-term fundamentals and declining investor participation.

As of 18-Jan, TCM Ltd's stock price is rising slightly, currently at 58.10, with a change of 0.1 (0.17%) increase. This upward movement can be attributed to a couple of factors. Firstly, the stock has been gaining for the last two days, with a total return of 0.47% during this period, indicating a short-term positive trend. Additionally, the stock's performance today is reported to be inline with its sector, which may contribute to investor confidence.<BR><BR>However, it is important to note that despite this recent rise, TCM Ltd has faced significant challenges. Over the past month, the stock has decreased by 13.08%, and year-to-date, it is down 9.42%. The company has reported operating losses and has a high Debt to EBITDA ratio of -1.00 times, indicating a weak long-term fundamental strength. Furthermore, the company has shown negative financial results, including a PAT of Rs -0.78 crore, which has fallen by 36.8%, and a decline in net sales by 14.20%.<BR><BR>While the stock has generated a commendable return of 26.30% over the past year, outperforming the market, the underlying financial struggles and falling investor participation, evidenced by a 54.27% drop in delivery volume, suggest that the stock's rise may be temporary and could be overshadowed by its long-term weaknesses.

Which are the latest news on TCM?